Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry

Rodriguezrosas, M; Lofwall, Michelle R.; Strain, Eric C.; Siluk, Danuta; Wainer, Irving W.

doi:10.1016/j.jchromb.2006.11.025

Cited by 38 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This assay satisfied sensitivity requirements with limits of quantification of 0.1 ng/mL for BUP and BUP-Gluc, and 0.5 ng/mL for NBUP and NBUP-Gluc. Other published methods achieved similar or better LOQ for BUP and NBUP [1,18,23,39,41,43,51,52]; however, none fulfilled compound identification criteria [45,46] due to monitoring of only a single ion [23,41,42], the surviving transition ion [18,39,43], or only one characteristic transition [1,52]. Favretto et al [25] achieved 0.1 ng/mL LOQ for BUP and NBUP with an ion trap mass spectrometer performing quantification in SRM mode.…”

Section: Discussionmentioning

confidence: 91%

“…With an upper LOQ of 10 ng/mL [18,25,39–41,52], dilution was unavoidable in many cases. Two methods [15,25] evaluated dilution integrity, but dilution was done with water instead of blank plasma [15] or blood [25].…”

Section: Discussionmentioning

confidence: 99%

“…LCMS and LCMSMS have been applied for BUP and metabolites’ analysis in a wide variety of matrices including, urine [1,19–28], hair [21,23,25,29–32], sweat [33], meconium [34], breast milk [35], placenta [36], and umbilical cord [37]. In plasma, several methods were published for BUP alone [18,38], BUP and NBUP [23,39–41]; BUP, NBUP, and glucuronides after hydrolysis [25,42]; BUP, NBUP and BUPG [43]; and all four analytes [1,15,44]. For compound identification by LCMSMS, FDA [45] and European guidelines [46] require chromatographic separation, a minimum of 2 transitions per analyte or 3 characteristic ions if LCMS (single MS) is employed, and acceptable relative ion intensities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women

Concheiro

Jones

Johnson

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

An LCMSMS method was developed and fully validated for the simultaneous quantification of buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) in 0.5mL plasma, fulfilling confirmation criteria with 2 transitions for each compound with acceptable relative ion intensities. Transitions monitored were 468.3>396.2 and 468.3>414.3 for BUP, 414.3>340.1 and 414.3>326.0 for NBUP, 644.3>468.1 and 644.3>396.3 for BUP-Gluc, and 590.3>414.3 and 590.3>396.2 for NBUP-Gluc. Linearity was 0.1–50 ng/mL for BUP and BUP-Gluc, and 0.5–50 ng/mL for NBUP and NBUP-Gluc. Intra-day, inter-day, and total assay imprecision (%RSD) were <16.8%, and analytical recoveries were 88.6–108.7%. Extraction efficiencies ranged from 71.1–87.1%, and process efficiencies 48.7–127.7%. All compounds showed ion enhancement, except BUP-Gluc that demonstrated ion suppression: variation between 10 different blank plasma specimens was <9.1%. In 6 umbilical cord plasma specimens from opioid-dependent pregnant women receiving 14–24 mg/day BUP, NBUP-Gluc was the predominant metabolite (29.8±7.6 ng/mL), with BUP-Gluc (4.6±4.8 ng/mL), NBUP (1.5±0.8 ng/mL) and BUP (0.4±0.2 ng/mL). Although BUP biomarkers can be quantified in umbilical cord plasma in low ng/mL concentrations, the significance of these data as predictors of neonatal outcomes is currently unknown.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women

Concheiro

Jones

Johnson

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

show abstract

“…It is also not detected by morphine-specific opiate immunoassay screening tests (see Table 1). Immunoassay [30], GC-MS [75][76][77], and LC-MS [78][79][80][81][82] methods that are specific for buprenorphine are available and should be used when detection of this drug is required.…”

Section: Buprenorphinementioning

confidence: 99%

Laboratory Testing for Prescription Opioids

Milone

2012

J. Med. Toxicol.

View full text Add to dashboard Cite

Opioid analgesic misuse has risen significantly over the past two decades, and these drugs now represent the most commonly abused class of prescription medications. They are a major cause of poisoning deaths in the USA exceeding heroin and cocaine. Laboratory testing plays a role in the detection of opioid misuse and the evaluation of patients with opioid intoxication. Laboratories use both immunoassay and chromatographic methods (e.g., liquid chromatography with mass spectrometry detection), often in combination, to yield high detection sensitivity and drug specificity. Testing methods for opioids originated in the workplace-testing arena and focused on detection of illicit heroin use. Analysis for a wide range of opioids is now required in the context of the prescription opioid epidemic. Testing methods have also been primarily based upon urine screening; however, methods for analyzing alternative samples such as saliva, sweat, and hair are available. Application of testing to monitor prescription opioid drug therapy is an increasingly important use of drug testing, and this area of testing introduces new interpretative challenges. In particular, drug metabolism may transform one clinically available opioid into another. The sensitivity of testing methods also varies considerably across the spectrum of opioid drugs. An understanding of opioid metabolism and method sensitivity towards different opioid drugs is therefore essential to effective use of these tests. Improved testing algorithms and more research into the effective use of drug testing in the clinical setting, particularly in pain medicine and substance abuse, are needed.

show abstract

“…Although numerous LC/MS methods have been published, almost none were able to combine selectivity, sensitivity, quantification of methadone and its two metabolites (EDDP and EMDP), less specimen volume and shorter specimen processing time [20][21][22][23][24][25][26][27]. Quintela et al reported an LC/MS assay that measured concentrations of methadone and EDDP in plasma [20].…”

Section: Introductionmentioning

confidence: 99%

Validation of a LC–APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation

Shakleya

Jansson

Huestis

2007

Journal of Chromatography B

View full text Add to dashboard Cite

Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry

Cited by 38 publications

References 32 publications

Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women

Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women

Laboratory Testing for Prescription Opioids

Validation of a LC–APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation

Contact Info

Product

Resources

About